DESTINY-Breast03 Phase 3 Study Results
Safety Update Overview (September 7, 2021)
T-DXd
n = 257
T-DM1
n = 261
n(%)
Patients discontinued from study treatment
141 (54.9)
222 (85.1)
Any grade TEAE
256 (99.6)
249 (95.4)
Grade ≥3 TEAE
137 (53.3)
130 (49.8)
Any grade serious TEAE
54 (21.0)
50 (19.2)
Grade 3 serious TEAE
39 (15.2)
38 (14.6)
TEAE associated with drug discontinuation
38 (14.8)
19 (7.3)
TEAE associated with dose reduction
59 (23.0)
36 (13.8)
T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event.
Safety update: Sept 7, 2021
ASCO 2022 #1000 Oral
DESTINY-Breast03
Daiichi-Sankyo
Rates of TEAEs (any grade and
grade ≥3) and serious TEAEs were
similar between the T-DXd and
T-DM1 arms
TEAEs associated with drug
discontinuation occurred in
38 patients (14.8%) in the
T-DXd arm and 19 patients
(7.3%) in the T-DM1 arm
26View entire presentation